The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
UroGen Pharma Ltd (NASDAQ: URGN) closed the day trading at $7.05 up 0.43% from the previous closing price of $7.02. In other words, the price has increased by $0.43 from its previous closing price. On the day, 2.3 million shares were traded.
Ratios:
For a better understanding of URGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 5.65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 09 ’25 when Schoenberg Mark bought 5,162 shares for $7.37 per share.
Schoenberg Mark sold 4,551 shares of URGN for $50,698 on Jan 31 ’25. The Chief Medical Officer now owns 145,666 shares after completing the transaction at $11.14 per share. On Jan 31 ’25, another insider, Smith Jason Drew, who serves as the General Counsel of the company, sold 7,379 shares for $11.14 each. As a result, the insider received 82,202 and left with 26,468 shares of the company.
Stock Price History:
Over the past 52 weeks, URGN has reached a high of $20.70, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is -19.22%, while the 200-Day Moving Average is calculated to be -35.78%.
Shares Statistics:
A total of 46.10M shares are outstanding, with a floating share count of 38.89M. Insiders hold about 15.66% of the company’s shares, while institutions hold 91.87% stake in the company.
